NZ596025A - [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto - Google Patents

[4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto

Info

Publication number
NZ596025A
NZ596025A NZ596025A NZ59602506A NZ596025A NZ 596025 A NZ596025 A NZ 596025A NZ 596025 A NZ596025 A NZ 596025A NZ 59602506 A NZ59602506 A NZ 59602506A NZ 596025 A NZ596025 A NZ 596025A
Authority
NZ
New Zealand
Prior art keywords
formula
compound
reacting
quinazolin
sulfonylureas
Prior art date
Application number
NZ596025A
Other languages
English (en)
Inventor
Xiaoming Zhang
Hilary Cannon
Robert M Scarborough
Craig M Grant
Mukund Mehrotra
Wolin Huang
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of NZ596025A publication Critical patent/NZ596025A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
NZ596025A 2005-11-03 2006-11-03 [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto NZ596025A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73365005P 2005-11-03 2005-11-03
NZ567747A NZ567747A (en) 2005-11-03 2006-11-03 [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto

Publications (1)

Publication Number Publication Date
NZ596025A true NZ596025A (en) 2013-08-30

Family

ID=38023842

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ567747A NZ567747A (en) 2005-11-03 2006-11-03 [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
NZ596025A NZ596025A (en) 2005-11-03 2006-11-03 [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ567747A NZ567747A (en) 2005-11-03 2006-11-03 [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto

Country Status (20)

Country Link
US (3) US8058284B2 (enExample)
EP (2) EP2428514A1 (enExample)
JP (1) JP5509406B2 (enExample)
KR (1) KR101423483B1 (enExample)
CN (1) CN101300013B (enExample)
AR (1) AR056762A1 (enExample)
AT (1) ATE540034T1 (enExample)
AU (1) AU2006311795B2 (enExample)
BR (1) BRPI0618210A2 (enExample)
CA (1) CA2627719C (enExample)
CY (1) CY1112826T1 (enExample)
DK (1) DK1951254T3 (enExample)
EA (1) EA017402B1 (enExample)
ES (1) ES2380814T3 (enExample)
IL (1) IL191193A (enExample)
NZ (2) NZ567747A (enExample)
PT (1) PT1951254E (enExample)
TW (2) TWI397529B (enExample)
WO (2) WO2007056167A2 (enExample)
ZA (1) ZA200804241B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521470B2 (en) 2004-06-18 2009-04-21 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
KR101423483B1 (ko) * 2005-11-03 2014-07-28 포톨라 파마슈티컬스, 인코포레이티드 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법
MX2008014193A (es) 2006-05-05 2009-03-31 Millennium Pharm Inc Inhibidores del factor xa.
WO2008133155A1 (ja) 2007-04-19 2008-11-06 Astellas Pharma Inc. 二環式ヘテロ環化合物
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
JP2010526101A (ja) 2007-05-02 2010-07-29 ポートラ ファーマシューティカルズ， インコーポレイテッド 直接作用型および可逆的ｐ２ｙ１２阻害剤の静脈および経口投与
JP2010526105A (ja) * 2007-05-02 2010-07-29 ポートラ ファーマシューティカルズ， インコーポレイテッド ［４−（６−フルオロ−７−メチルアミノ−２，４−ジオキソ−１，４−ジヒドロ−２ｈ−キナゾリン−３−イル）−フェニル］−５−クロロ−チオフェン−２−イル−スルホニルウレア塩、異なる結晶形態、その医薬組成物
CN101686959B (zh) * 2007-05-02 2014-05-07 波托拉医药品公司 作为血小板adp受体抑制剂的化合物的组合疗法
CA2690243A1 (en) * 2007-06-18 2008-12-24 Sanofi-Aventis Pyrrole derivatives as p2y12 antagonists
CN101654441B (zh) * 2008-08-19 2012-10-03 信谊药厂 抗凝化合物、组合物及其用途
JP2012508773A (ja) * 2008-11-14 2012-04-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 低いｐＨでの難水溶性のイオン化活性薬剤の制御放出のための固体組成物およびその使用方法
WO2011006169A1 (en) 2009-07-10 2011-01-13 Portola Pharmaceuticals, Inc. Methods for diagnosis and treatment of thrombotic disorders mediated by cyp2c19*2
WO2011024933A1 (ja) 2009-08-28 2011-03-03 第一三共株式会社 ３－（ビアリールオキシ）プロピオン酸誘導体
CN102762550B (zh) 2009-12-17 2015-04-01 米伦纽姆医药公司 Xa因子抑制剂的盐和结晶形式
US8742120B2 (en) 2009-12-17 2014-06-03 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
WO2011088152A1 (en) 2010-01-12 2011-07-21 Portola Pharmaceuticals, Inc. Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011137459A1 (en) 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
JP2013544271A (ja) * 2010-12-03 2013-12-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 式（ｉ）の化合物の薬学的組成物、投薬形態、および新規の形態、ならびにその使用方法
JP6268093B2 (ja) * 2012-09-14 2018-01-24 キッセイ薬品工業株式会社 縮合複素環誘導体の製造方法およびその製造中間体
RU2556198C1 (ru) * 2014-04-10 2015-07-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук Способ профилактики развития постперикардиотомного синдрома у больных ишемической болезнью сердца, подвергшихся коронарному шунтированию
WO2017003723A1 (en) 2015-07-01 2017-01-05 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. MODULATORS OF SOMATOSTATIN AND USES THEREOF
US12180193B2 (en) 2020-08-28 2024-12-31 Arvinas Operations, Inc. Accelerating fibrosarcoma protein degrading compounds and associated methods of use
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE845042C (de) 1950-07-14 1952-07-28 Basf Ag Verfahren zur Herstellung von Sulfonylurethanen, -harnstoffen oder -carbonsaeureamiden
US3847925A (en) 1971-07-15 1974-11-12 En Nom Collectif Science Et Ci Benzenesulfonyl semicarbazides
DE3134780A1 (de) * 1981-09-02 1983-03-10 Hoechst Ag, 6000 Frankfurt "sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung"
US4720450A (en) * 1985-06-03 1988-01-19 Polaroid Corporation Thermal imaging method
GB9413975D0 (en) 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
US5314902A (en) 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
US6268380B1 (en) 1993-02-19 2001-07-31 G. D. Searle & Co. Urea derivatives useful as platelet aggregation inhibitors
US5614539A (en) 1993-03-15 1997-03-25 G. D. Searle & Co. Urea compounds which are useful as platelet aggregation inhibitors
JPH0881442A (ja) 1994-07-14 1996-03-26 Otsuka Pharmaceut Co Ltd 環状アミド誘導体
TW448161B (en) 1994-07-14 2001-08-01 Otsuka Pharma Co Ltd Cyclic amide derivatives
US6413724B1 (en) 1996-10-28 2002-07-02 Versicor, Inc. Solid phase and combinatorial library syntheses of fused 2,4-pyrimidinediones
US6160000A (en) * 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
JPH10195323A (ja) 1997-01-09 1998-07-28 Nippon Paper Ind Co Ltd 新規なスルホニルグアニジン化合物及びそれを用いた感熱記録体
SE9702774D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
JP2002509152A (ja) 1998-01-15 2002-03-26 シーオーアール セラピューティクス インコーポレイテッド 血小板ａｄｐ受容体阻害剤
JP2000204081A (ja) 1998-02-05 2000-07-25 Takeda Chem Ind Ltd スルホンアミド誘導体、その製造法及び用途
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
ATE309999T1 (de) 2000-02-04 2005-12-15 Portola Pharm Inc Blutplättchen-adp-rezeptor-inhibitoren
DE60144284D1 (de) 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
EP1474108A2 (en) * 2002-01-09 2004-11-10 Enzrel, Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
US20040242658A1 (en) 2003-01-08 2004-12-02 Dr. Reddy's Laboratories Limited Amorphous form of rosiglitazone maleate and process for preparation thereof
DE602004024093D1 (de) 2003-10-03 2009-12-24 Portola Pharm Inc 2,4-dioxo-3-chinazolinylarylsulfonylharnstoffe
KR101423483B1 (ko) * 2005-11-03 2014-07-28 포톨라 파마슈티컬스, 인코포레이티드 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법
JP2010526101A (ja) * 2007-05-02 2010-07-29 ポートラ ファーマシューティカルズ， インコーポレイテッド 直接作用型および可逆的ｐ２ｙ１２阻害剤の静脈および経口投与
JP2010526105A (ja) * 2007-05-02 2010-07-29 ポートラ ファーマシューティカルズ， インコーポレイテッド ［４−（６−フルオロ−７−メチルアミノ−２，４−ジオキソ−１，４−ジヒドロ−２ｈ−キナゾリン−３−イル）−フェニル］−５−クロロ−チオフェン−２−イル−スルホニルウレア塩、異なる結晶形態、その医薬組成物
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto

Also Published As

Publication number Publication date
TWI397529B (zh) 2013-06-01
EA200801245A1 (ru) 2008-10-30
CY1112826T1 (el) 2016-02-10
KR101423483B1 (ko) 2014-07-28
US8058284B2 (en) 2011-11-15
CA2627719C (en) 2016-07-12
US20120088736A1 (en) 2012-04-12
KR20080071167A (ko) 2008-08-01
BRPI0618210A2 (pt) 2011-08-23
ATE540034T1 (de) 2012-01-15
EP1951254A2 (en) 2008-08-06
IL191193A (en) 2014-04-30
JP2009515836A (ja) 2009-04-16
EA017402B1 (ru) 2012-12-28
WO2007056167A2 (en) 2007-05-18
CN101300013B (zh) 2012-11-28
US20070123547A1 (en) 2007-05-31
WO2007056219A3 (en) 2007-12-27
EP1951254A4 (en) 2009-05-27
EP2428514A1 (en) 2012-03-14
ZA200804241B (en) 2009-09-30
JP5509406B2 (ja) 2014-06-04
AU2006311795A1 (en) 2007-05-18
DK1951254T3 (da) 2012-05-07
WO2007056219A2 (en) 2007-05-18
AU2006311795B2 (en) 2013-01-17
NZ567747A (en) 2011-11-25
CN101300013A (zh) 2008-11-05
ES2380814T3 (es) 2012-05-18
TW200728260A (en) 2007-08-01
HK1121051A1 (en) 2009-04-17
TW200804356A (en) 2008-01-16
CA2627719A1 (en) 2007-05-18
AR056762A1 (es) 2007-10-24
EP1951254B1 (en) 2012-01-04
US20070208045A1 (en) 2007-09-06
WO2007056167A3 (en) 2007-10-04
PT1951254E (pt) 2012-04-12

Similar Documents

Publication Publication Date Title
NZ596025A (en) [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
IL175024A0 (en) Method for producing 2-dihaloacyl-3-amino-acrylic acid esters and 3-dihalomethyl-pyrazole-4-carboxylic acid esters
GEP20094804B (en) Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
TN2011000326A1 (en) Quinazolinone derivatives useful as vanilloid antagonits
SG179206A1 (en) Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
NO20074055L (no) Prosesser for a fremstille 4-(fenoksy-5-metylpyrimidin-4-yloksy)piperidin-1-karboksylsyrederivater og relaterte forbindelser
TW201609694A (zh) 用於製備３－（３－氯－１ｈ－吡唑－１－基）吡啶的方法（一）
SG158848A1 (en) Method for producing annelated piperazin-2-one derivatives and intermediates of said method
BRPI0414059A (pt) sìntese seletiva de pirimidinas substituìdas em cf3
WO2009045988A3 (en) New organic fluorescent sulfonyl ureido benzoxazinone pigments
CA2461060A1 (en) Method for preparing pyrimidinone compound and pharmaceutically acceptable salts thereof
ZA201003751B (en) Process for the synthesis of propargylated aminoindan derivatives
NO20071253L (no) Fremgangsmate for syntese av C-2, C-3 substituerte N-alkylerte indoler anvendbare som CPLA2-inhibitorer.
WO2006070349A3 (en) Novel process for preparing pramipexole and its optical isomeric mixture by reduction with sodium triacetoxyborohydride
NO20081859L (no) Fremgangsmate for fremstillingen av sartanderivater og mellomprodukter som er nyttige i slike fremgangsmater
TW200640830A (en) Process for the preparation of intermediates
PT1893589E (pt) Derivados substituídos de n-benzo[d]isoxazol-3-il-amina como inibidores de recetores mglur5, recetores de serotonina-(5-ht) e recetores de noradrenalina e sua utilização na produção de medicamentos
CA2647590A1 (en) Process for production of ethylenediamine derivatives having halogenated carbamate group and acyl group, and intermediates for production of the derivatives
ATE538102T1 (de) Verfahren zur herstellung eines chinazolinderivats
EA200700767A1 (ru) Способ получения пиразолов
TW200740763A (en) A method for preparing 5-hydroxy-1-alkyl pyrazole derivatives
ATE555095T1 (de) Verfahren zur herstellung von 3-hydroxy-n-alkyl-1-cycloalkyl-6-alkyl-4-oxo-1, -dihydropyridin-2- carbonsäureamid und damit verwandten analoga
EA200901174A1 (ru) Способ получения замещенных фенилгидразинов
DE602006005230D1 (de) Verfahren zur herstellung von 2-azabicycloä3.3.0üoctan-3-carbonsäurederivaten
KR101348440B1 (ko) 퀴나졸린-2,4-다이온 유도체의 원-팟 합성방법

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE MISSING INVENTOR HAS BEEN ADDED (1201825, SCARBOROUGH, ROBERT M; 1201826, HUANG, WOLIN; 1201827, MEHROTRA, MUKUND; 1201828, ZHANG, XIAOMING; 1201829, CANNON, HILARY; 1201830, GRANT, CRAIG M)

Effective date: 20130211

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 03 NOV 2016 BY DENNEMEYER SA

Effective date: 20131220

S23 Proceedings under section 23: mention of inventor as such in patent

Free format text: INVENTOR ANDRE, PATRICK , CONLEY, PAMELA B., PANDEY, ANJALI , PHILIPS, DAVID R. , SINHA, UMA ADDED

Effective date: 20140130

ERR Error or correction

Free format text: THE INVENTOR HAS BEEN CORRECTED TO 1201825, SCARBOROUGH, ROBERT M; 1201826, HUANG, WOLIN; 1201827, MEHROTRA, MUKUND; 1201828, ZHANG, XIAOMING; 1201829, CANNON, HILARY; 1201830, GRANT, CRAIG M; 3116095, PANDEY, ANJALI , 4506 AMIENS AVENUE, FREMONT, CALIFORNIA 94555, US; 3116097, CONLEY, PAMELA B., 116 LOIS LANE, PALO ALTO, CALIFORNIA 94303, US; 3116099, ANDRE, PATRICK , 950 N. HUMBOLDT STREET, SAN MATEO, CALIFORNIA 94401, US; 3116103, SINHA, UMA , 808 JUNIPERO SERRA BOULEVARD, SAN FRANCISCO, CALIFORNIA 94127, US; 3117788, PHILLIPS, DAVID R., 520 HARVARD ROAD, SAN MATEO, CALIFORNIA 94402, US

Effective date: 20140227

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 NOV 2017 BY DENNEMEYER + CO.

Effective date: 20161021

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 NOV 2018 BY DENNEMEYER + CO

Effective date: 20171025

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 NOV 2019 BY DENNEMEYER + CO

Effective date: 20181020

LAPS Patent lapsed